Vireo Growth (VREOF) Revenue Growth (1y) (2021 - 2026)
Vireo Growth (VREOF) Revenue Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.96 Bn | 32.22 Bn | 1.97 Bn | 2.34% |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | 2.91% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -11.85% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | -1.62% |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | 7.85% |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | 42.25% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 14.92% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 333.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 333.47% |
| Dec 31, 2025 | 317.65% |
| Sep 30, 2025 | 264.21% |
| Jun 30, 2025 | 91.42% |
| Mar 31, 2025 | 1.71% |
| Dec 31, 2024 | 3.52% |
| Sep 30, 2024 | 1.99% |
| Jun 30, 2024 | 24.32% |
| Mar 31, 2024 | 26.19% |
| Dec 31, 2023 | 26.94% |
| Sep 30, 2023 | 30.87% |
| Jun 30, 2023 | -4.24% |
| Mar 31, 2023 | 22.06% |
| Dec 31, 2022 | 39.45% |
| Sep 30, 2022 | 41.02% |
| Jun 30, 2022 | 48.20% |
| Mar 31, 2022 | 18.56% |
| Dec 31, 2021 | 10.11% |
| Sep 30, 2021 | 7.16% |
| Jun 30, 2021 | 16.50% |